Abstract:Polycystic ovary syndrome (PCOS) is a diagnosis made between late adolescence and the menopause in 5-10% of women. PCOS is a heterogeneous disorder of unknown etiology characterized by hyperandrogenic chronic anovulation. This syndrome consists of a diverse constellation of signs and symptoms, such as hirsutism, acne, acanthosis nigricans, obesity, menstrual irregularities, anovulation, and/or infertility. Features of the metabolic syndrome, including obesity, insulin resistance, and dyslipidemia, are common in this patient population. Recent insights into the pathophysiology of PCOS have shown insulin resistance and hyperinsulinemia to play a substantial role. Insulin resistance is increasingly recognized as a chronic, low-level, inflammatory state. Recent studies show that serum levels of inflammatory mediators, such as tumor necrosis factor-alpha and interleukin-6, are increased in the insulin-resistant conditions of obesity and PCOS. The optimal modality for long-term treatment should have positive effects on androgen synthesis, sex hormone-binding globulin production, the lipid profile, insulin sensitivity, inflammatory mediators, and clinical symptoms including acne, hirsutism, and irregular menstrual cycles. Treatment with insulin-sensitizing agents is a relatively new therapeutic strategy in women with PCOS. Current research has shown that the use of diabetes mellitus management practices aimed at reducing insulin resistance and hyperinsulinemia (such as weight reduction and the administration of oral antidiabetic drugs) can not only reverse testosterone and luteinizing hormone abnormalities and restore menstrual cycles, but can also improve glucose, insulin, proinflammatory cytokine, and lipid profiles.Clinical treatment with troglitazone, a member of the thiazolidinedione family, for the management of PCOS complications such as insulin resistance, hyperandrogenism, and anovulation was found to have beneficial effects; however, it was taken off the market over concerns of hepatotoxicity. Although troglitazone is no longer available in the US, numerous clinical trials have established the role of thiazolidinediones in the treatment of women with PCOS. Clinical data emerging regarding the utility of two of the newer, safer thiazolidinediones, pioglitazone and rosiglitazone, for this patient population, consistently demonstrate effective improvements of endocrine and ovulatory performance in women with PCOS. The benefit and importance of lifestyle modification and weight reduction, when it can be achieved, is still an important component in the long-term treatment of PCOS. Pharmacologic reduction in insulin levels using thiazolidinediones appears to offer another therapeutic modality for PCOS, which may ameliorate the progress of both hyperinsulinemia and hyperandrogenism. However, additional studies of patients so treated are necessary before these agents can be considered first-line treatment for PCOS. Convincing data from randomized controlled trials with sufficient power to detect both the benefits and risks of long-term treatment with thiazolidinediones in women with PCOS remain to be obtained.

Effect of Thiazolidinedione Amide on Insulin Resistance, C-Reactive Protein and Endothelial Function in Young Women with Polycystic Ovary Syndrome

Thiazolidinediones Improving the Insulin Resistance in Women with PCOS

Association of Serum Thyroid Hormone Levels with Androgen and Metabolic Parameters in Chinese Women with Polycystic Ovary Syndrome: A Retrospective Cross-Sectional Study

The efficacy and safety of insulin-sensitizing drugs for treatment of polycystic ovary syndrome:a Meta-analysis

Thiazolidinediones for the therapeutic management of polycystic ovary syndrome : impact on metabolic and reproductive abnormalities

[Efficacy and metabolic safety of long-term treatment with ethinyl oestradiol/cyproterone and desogestrel/ethinyl oestradiol tablets in women with polycystic ovary syndrome]

Beneficial effects of pioglitazone and α-lipoic acid in patients with polycystic ovaries syndrome

Effects of vitamin D supplementation on metabolic parameters in women with polycystic ovary syndrome: a randomized controlled trial

Effects and mechanisms of DanZhi XiaoYao power on insulin resistance in polycystic ovary syndrome rats

Effects of GLP-1R agonist or co-cyprindiol, in combination with metformin, on polycystic ovary syndrome in overweight women: A Randomized Clinical Trial

Insulin Sensitivity in Non-obese and Non-insulin Resistance Women with Polycystic Ovary Syndrome During Treatment with Diane-35

Clinical Efficacy of Pioglitazone with Ethinylestradiol-cyproterone Acetate for Treatment of Polycystic Ovary Syndrome

Insulin Sensitizers for Improving the Endocrine and Metabolic Profile in Overweight Women With PCOS

Effects of Diane-35 on the glucose and lipid metabolism in patients with polycystic ovary syndrome

The Effects of Omega-3 Fatty Acids and Vitamin E Co-Supplementation on Indices of Insulin Resistance and Hormonal Parameters in Patients with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial

Omega-3 Fatty Acids Improve Glucose Metabolism without Effects on Obesity Values and Serum Visfatin Levels in Women with Polycystic Ovary Syndrome

861-P: Efficacy of Digital Intervention Vs. Metformin for Women with Polycystic Ovary Syndrome—A Randomized Clinical Trial

Influence of metformin combined with Gexia Zhuyu Tang on inflammatory factors and sex hormone level in rats with polycystic ovarian syndrome

Preliminary Study of Curative Effect of Rosiglitazone and Metformin in Women with Polycystic Ovarian Syndrome

Effect of Short-Term Treatment with Metformin on Psychological Distress and Metabolic Feature in Patients with Polycystic Ovary Syndrome

Insulin Resistance in Polycystic Ovary Syndrome Improved by Chinese Medicine Dingkun Pill (???): A Randomized Controlled Clinical Trial